Novo Nordisk Grapples with Supply Shortage Amid Surging Demand for Weight-Loss Drugs
Novo Nordisk is facing a supply shortage for its weight-loss drugs, Wegovy and Saxenda, due to surging demand… Here’s What [...]
ITIF Report: Global Drug Price Controls Restrict Pharmaceutical Research and Development
The Information Technology and Innovation Foundation (ITIF) study reports that drug price controls in non-US Organization for Economic Cooperation and [...]
Economists Suggest That Universal Coverage Is Already Possible for the US: What Obstacles Still Stand in the Way?
The current state of health insurance in the U.S. needs to be revised, even for insured Americans who face the [...]
BridgeBio’s Experimental Results Boosts Company Shares by 65%
BridgeBio Pharma Inc's experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its [...]
FDA Approves AstraZeneca’s Beyfortus
The Food and Drug Administration has approved an AstraZeneca-developed monoclonal antibody, Beyfortus, in an effort to protect infants and young [...]
J&J Subsidiary Sues Doctors Over Talc-Cancer Research
Johnson & Johnson's subsidiary LTL Management has filed lawsuits against four doctors who have published studies suggesting links between J&J's [...]
Revolution in Women’s Health: First Over-The-Counter Contraceptive Coming to U.S. Shelves in 2024!
Perrigo's oral contraceptive, Opill, is now the first over-the-counter birth control pill in the United States. Opill has been around [...]
Sequoia Project and AHIMA Launch Health Data Usability Project
The Sequoia Project and the American Health Information Management Association (AHIMA) have partnered on the initiative "Data Usability Taking Root." [...]
BioGeneration Ventures Finalizes $167M Fund for Biotech Startups in Europe
What You Need To Know: Dutch venture capital firm BioGeneration Ventures (BGV) has secured €150 million ($167 million) for its [...]
Insights into the Global Real World Evidence Solutions Market 2023-2030
10 Things You Need to Know: The projection shows the market size growing from $16.3 billion in 2023 to $36.24 [...]
Unmasking Healthcare Costs: Beyond Transparency
What You Need to Know: Policymakers have shifted focus towards price transparency in healthcare to combat escalating costs; however, merely [...]
Is AI the Future of Pharma?
Here's What People Are Saying... ChatGPT is revolutionizing the pharmaceutical industry. Artificial intelligence and machine learning are expediting medication development, [...]
Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster
What You Need to Know: Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira [...]
Will the Medicare Price Negotiation Revamp Sufficiently Appease Pharma Companies?
The Centers for Medicare & Medicaid Services (CMS) amendments to its drug pricing negotiation program will unlikely deter past, current, [...]
Thermo Fisher to Acquire Data Firm CorEvitas for $912.5M
What You Need to Know: For $912.5 million, Thermo Fisher Scientific is set to acquire CorEvitas, a real-world data intelligence [...]
ICER to Perform Value-Assessment for KarXT Schizophrenia Treatment
The Institute for Clinical and Economic Review (ICER) will perform a value-assessment on KarXT (xanomeline tartrate/trospium chloride), Karuna Therapeutics’ experimental therapeutic for schizophrenia. Public discussion of the assessment will take place next February at the 2024 New England CEPAC meeting.
Looking to the Future of AI in Healthcare
Artificial Intelligence (AI) is increasingly being incorporated into every aspect of society, including healthcare. From diagnostics to reimbursement, AI is taking a foothold in healthcare and medicine from drug development to the clinic. However, significant barriers to realizing the potential of the technology still remain.
Study Explores Real-World Data Reporting Quality According to RECORD Statement
With the rise of real-world data (RWD) and real-world evidence (RWE), a lack of transparency impairs reproducibility and quality assessment. The Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement was drafted to help address this issue. A newly published study in BMC Medical Research Methodology explores reporting quality in RWD studies using the RECORD checklist.
Tips for Managed Care to Approach Value-Based Care
The shift towards value-based care has the potential to benefit patients, providers, and payers alike, but it brings about unique challenges for managed care plans. In a new Managed Healthcare Executive article, learn more about value-based care payment models and strategies to apply them successfully in managed care organizations.
EMA Releases Report on Real-World Evidence
The European Medicines Agency published a report last week discussing the use of real-world evidence (RWE) in clinical trials and regulatory decisionmaking, the benefits it can provide, and the challenges in doing so. RWE, according to the report, is widely used in pharmacovigilance studies, but its use in early drug development still faces uncertainties.
From Analysis to Action: Exploring Health Equity with Aletha Maybank
In a new interview with Nature, senior vice president and chief health equity officer at the American Medical Association (AMA) Aletha Maybank, MD, MPH, speaks about her work analyzing the processes underlying health disparities and how they can be targeted to promote better outcomes in marginalized populations.
New Real-World Evidence from AstraZeneca Finds Medication Discontinuation Worsens Hyperkalemia
New real-world evidence (RWE) presented at this year’s European Renal Association Congress explored hypokalemia care, finding that reduction or discontinuation of renin-angiotensin-aldosterone system inhibitor (RAASi) worsens outcomes of patients admitted for hyperkalemia (HK), high calcium levels in blood. RWE from the ZORA study shows that few patients have their RAASi medications reinitiated after a hyperkalemia event, which is associated with a two times increase in mortality.
The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions
In this interview with Chad Rose, General Manager of hēRo3, he explains how biopharma is incorporating critical HEOR insights [...]
How New CMS Rules to Cut Appointment Wait Times Will Affect Managed Care
Research shows that new patients have to wait an average of 26 days for an appointment in 15 major US cities. To tackle this problem, the Centers for Medicare and Medicaid Services (CMS) recently proposed a rule entitled the Notice of Proposed Rulemaking Managed Care Access, Finance, and Quality (NPRM). The NPRM would cap appointment wait times for primary care, mental health, and substance use disorder treatment.
First Lawsuit Against US Medicare Drug Pricing Negotiations Filed by Merck
The pharma giant Merck & Co has filed a lawsuit against the US government over upcoming Medicare drug pricing negotiations included in the Inflation Reduction Act passed last year. The company argues that the negotiations would violate their 5th Amendment rights by forcing them to provide drugs at prices lower than market value.
